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ABSTRACT
This review of insulin pump therapy focuses 
on the OmniPod® Insulin Management System 
(Insulet Corp., Bedford, MA, USA). The OmniPod 
System is the first commercially available “patch 
pump.” It is a fully integrated wearable pump, 
controlled wirelessly through a handheld device 
containing a built-in blood glucose meter. This 
is an evaluation of the OmniPod System, with 
the aim of providing an educational tool for 
physicians who are considering recommending 
this  product  to  their  patients.  The  review 
includes a discussion of the traditional insulin 
pump  configuration  and  its  limitations,  a 
detailed  overview  of  the  OmniPod  System, 
references  to  clinical  study  data,  planned 
product enhancements, its use as an insulin 
delivery system in the Juvenile Diabetes Research 
Foundation’s Artificial Pancreas Project, and its 
use to deliver additional compounds.
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INTRODUCTION
This  review  is  intended  to  provide  an 
educational tool for physicians who want to 
recommend an insulin pump to their patients 
and need to learn about the current technologies 
available to them. The review focuses on the 
OmniPod® Insulin Management System (Insulet 
Corp.,  Bedford,  MA,  USA),  comparing  it  to 
traditional insulin pumps and explaining its 
value within the range of products.
Traditional Insulin Pump Therapy
Insulin  pumps  were  first  developed  for 
commercial use in the late 1970s. Over the past 
30 years, the components have changed little. 
The components of traditional pump systems 
used for diabetes management include:
A device about the size of a deck of cards that  •	
contains an insulin reservoir, a pumping 
mechanism,  batteries,  and  a  microchip 
that carries the user’s daily insulin delivery Diabetes Ther (2010)  1(1):10-24. 11
programs and delivery history. The device 
has a screen and buttons to aid the user in 
delivering the proper amount of insulin. 
Current pumps come with color screens, 
sleek outlines, and much-improved user 
interface. The patient usually wears the 
device in a pocket or hooked on a belt 
or waistband.
An infusion set that attaches to the patient’s  •	
skin with adhesive and includes a short 
plastic cannula that is inserted just beneath 
the skin to allow access for the insulin. The 
patient either uses a mechanical inserter 
to attach the set and insert the cannula, or 
inserts the infusion set by hand.
A length of tubing that delivers the insulin  •	
from the pump to the infusion set and 
cannula. Tubing ranges from 30 to 110 cm 
(11.8 to 43.3 inches).
A separate blood glucose (BG) monitor. The  •	
patient uses the result on the monitor to 
calculate the dosage of insulin s/he should 
take and then inputs that instruction to the 
pump. Most pumps also include a bolus 
calculator to assist with these calculations. 
(In recent years, more pumps have added 
linked  glucose  meters  that  convey  the 
BG  value  to  the  pump  for  correction 
bolus calculations.)
Table 1 lists insulin pump products currently 
available, alphabetically by manufacturer.
Benefits of Insulin Pump Therapy
Patients  using  multiple  daily  injections 
(MDI) typically inject four times a day or more, 
usually using two different types of insulin. 
The appeal of insulin pumps has been that 
they eliminate the need for these injections 
while allowing for greater customization and 
tailoring of insulin delivery. Insurers recognize 
the benefits to certain patients; for example, to 
get reimbursement for insulin pump therapy in 
the EU, the patient must have one or more of 
these indications:
Dawn phenomenon •	
Severe hypoglycemia unawareness •	
An irregular daily schedule, such as people  •	
who work various shifts or have unforeseen 
physical activities requiring a reduction of 
basal insulin
Pregnancy •	
Diabetes complications that require very  •	
tight glucose control.
Continuous subcutaneous insulin infusion 
(CSII) therapy is not limited to those populations. 
It can benefit any patient with type 1 diabetes. 
Use of an insulin pump frees the patient from 
the strict eating schedule required when using 
long- and intermediate-acting insulins, and 
allows increased flexibility in daily activities. 
While  the  basal  (or  background)  dosage  is 
preprogrammed, it can be changed as needed. 
Meal and correction boluses are given as needed 
during the course of the day. So, for example, 
if the patient has no appetite for breakfast,   
s/he can replace it with a small snack or nothing, 
Table 1. Insulin pump (continuous subcutaneous insulin 
infusion) products currently available.
Manufacturer Products
Animas Corp. OneTouch® Ping®
Insulet Corp. OmniPod® (available only in 
US and Israel)
mylife™ OmniPod®
Medtronic MiniMed, Inc. Paradigm®
Paradigm® Revel™
Nipro Diagnostics, Inc. Amigo® (available only in 
US, as of August 1, 2010)
Roche Diabetes Care (AG) Accu-Chek® Spirit
Accu-Chek® Combo  
(not available in US)
SOOIL Development DANA Diabecare®12 Diabetes Ther (2010)  1(1):10-24.
checking  periodically  that  the  BG  remains 
steady. Further, if the patient wants to exercise at 
any given time, s/he can reduce or halt the basal 
delivery for a specified time, add food intake, 
reduce the bolus prior to exercise, or all three, as 
needed—all while checking the BG periodically.
Limitations of Traditional Insulin Pump 
Therapy
While pumping is freeing in some respects, 
it is also an added responsibility. Because 
pumps use rapid-acting insulin analogs, any 
interruption in insulin delivery may result 
in  hyperglycemia  and  the  rapid  onset  of 
diabetic ketoacidosis. In addition, traditionally 
designed systems have a number of limitations 
that could be improved upon to allow more 
patients with diabetes to benefit from CSII 
therapy. These include:
Long tubing connects the insulin reservoir  •	
in a traditional pump to the infusion set. The 
tubing has to be managed by patients in all 
aspects of daily living (dressing, exercising, 
etc).  This  tubing  can  catch  on  things 
during daily use, resulting in disruption of 
insulin delivery.
The process of inserting the cannula with  •	
mechanical inserters or by hand is awkward 
and can result in variable cannula insertion 
angles  and  depths.  This  mechanical  or 
manual cannula insertion process can be 
intimidating to some patients.
Managing the large number of components  •	
required  during  setup  and  infusion  set 
changes is complex.
Locations  to  insert  infusion  sets  are  •	
relatively limited.
These limitations left room for innovation 
and  improvement,  which  the  designers  of 
the  OmniPod  Insulin  Management  System 
implemented in their design and development, 
described in detail in the next section.
THE OMNIPOD SYSTEM: WHAT IS 
IT AND HOW DOES IT WORK?
Insulin  pumps  are  not  all  the  same. 
Physicians and their patients need to choose a 
pump to fit the individual’s needs and lifestyle. 
The OmniPod System is quite innovative in 
resolving the limitations of traditional pumps 
listed above.
The OmniPod Insulin Management System 
is a novel insulin pump system designed by 
Insulet Corporation. The company was founded 
in 2000. In mid-2003, Insulet received its first 
501(k) clearance from the Food and Drug 
Administration (FDA) for the OmniPod System. 
In early 2005, the commercial version of the 
OmniPod System was cleared by the FDA, and 
the product was shipped to the first patient 
later that year. By the end of 2008, the System 
was available and supported in all 50 US states. 
As of July 2010, the System is available in the 
United Kingdom and Germany under the brand 
mylife™ OmniPod®, and will soon be launched 
in other EU countries along with Australia 
and China.
The OmniPod System has won three awards 
for innovation in both industrial design and 
medical technology design (see Table 2). These 
honors demonstrate that those in the larger 
medical area (but not directly concerned with 
Table 2. Design awards won by the OmniPod Insulin 
Management System.
Year Award
2006 Gold Industrial Design Excellence Award (IDEA) 
from the Industrial Designers Society of America
2006 Medical Design Excellence Award (MDEA) 
for General Hospital Devices and Therapeutic 
Products
2009 Edison Best New Product Award™ in the Science 
and Medical categoryDiabetes Ther (2010)  1(1):10-24. 13
diabetes) are also convinced that this device is a 
real improvement in therapy.
System Components
The Insulet OmniPod Insulin Management 
System  is  comprised  of  two  components 
(Figure 1): the OmniPod Disposable Infusion 
Pump (Pod) and the OmniPod Personal Diabetes 
Manager  (PDM),  which  incorporates  the 
FreeStyle® (Abbott Diabetes Care, Alameda, CA, 
USA) BG meter.
The PDM is a hand-held, battery-powered 
remote controller for the Pod (insulin pump). It 
has seven functional buttons, a back-lit liquid-
crystal colored display, and a BG meter. The PDM 
provides audio alarms, alerts, and reminders 
related to insulin delivery, reservoir level, Pod 
functioning, and battery life.
The  Pod  is  activated  and  controlled 
exclusively through use of the PDM. The Pod 
and  PDM  interact  wirelessly  using  secure, 
bidirectional  radio  frequency.  Wireless 
interaction  is  only  required  to  set  a  bolus 
delivery,  change  system  settings,  perform 
BG  measurements,  or  change  the  Pod;  in 
operation mode and during basal delivery, no 
wireless connection is needed, so the PDM does 
not need to be near the Pod. The Pod sounds an 
alarm if any attention is needed.
The Pod is a microprocessor-controlled device 
worn directly on the body. It delivers insulin 
based on the user’s custom-programmed basal 
rates and bolus doses for up to 3 days according 
to patient’s individual insulin needs.
Contraindications
Similar to traditional insulin pumps, the 
OmniPod  is  not  recommended  for  people 
who are:
Unable to perform at least four BG tests per  •	
day
Unable  to  maintain  contact  with  their  •	
healthcare provider
Unable  to  use  the  system  according  to  •	
instructions.
The integrated BG meter is not to be used for:
Testing newborns •	
Testing arterial blood •	
Diagnosing diabetes. •	
Detailed Product Description
The Pod
The Pod is a single-use disposable device. 
It is small, lightweight, and worn directly on 
the body. The adhesive on the base of the Pod 
keeps it securely in place for up to 3 days. The 
Pod incorporates a piezo ceramic resonator to 
provide audio alarms, alerts, and reminders.
Insulin is delivered through an integrated 
soft  cannula  in  the  Pod  that  is  inserted 
automatically into the subcutaneous tissue. 
Figure 1. OmniPod Insulin Management System.14 Diabetes Ther (2010)  1(1):10-24.
The cannula is inserted in five 1000ths of a 
second. The Pod is intended for use with rapid-
acting U-100 insulin: NovoLog® (Novo Nordisk 
A/S,  Copenhagen,  Denmark),  NovoRapid® 
(Novo  Nordisk  A/S),  Humalog®  (Eli  Lilly, 
Indianapolis, IA, USA), or Apidra® (Sanofi-
Aventis, Paris, France).
The  pad  on  the  base  of  the  Pod  uses  a 
standard,  commercially  available,  medical-
grade adhesive, designed for one-time use. Once 
removed, a Pod cannot be reapplied.
The Pod is watertight at a depth of 25 feet 
for  up  to  60  minutes  (IPX8).  Its  housing 
includes  a  viewing  window  at  the  infusion 
site, which allows the patient to inspect the 
insertion site for proper cannula placement and 
integrity. The Pod also includes a vent to ensure 
pressure equilibration with the surrounding 
environment. The housing does not have any 
elements that allow user access to the pump 
mechanism or electronics and it contains no 
user-serviceable parts.
Pod Motor Mechanism
The motor mechanism of the Pod incorporates 
microprocessor control, shape memory alloy 
(SMA) wire assembly (Figure 2), step sensor, and 
a motion sensor. The SMA wire assembly rotates 
the driveshaft/leadscrew, advances the piston 
within the reservoir, and delivers insulin through 
the  cannula.  Each  actuation  of  the  motor 
mechanism delivers 0.05 units of insulin.
Pod Insulin Reservoir
The  Pod  incorporates  a  fully  integrated 
insulin reservoir that holds up to 200 deliverable 
units of U-100 insulin (Figure 3). It requires no 
separate administration sets or reservoirs.
Fill Process
Each Pod is supplied with a fill syringe and 
a fill needle that are used to introduce insulin 
into the Pod. The fill syringe is sized to match 
the maximum fluid volume of the Pod with a 
self-stopping plunger rod that limits the amount 
of insulin it can contain. The syringe is clearly 
marked with the minimum fill volume (85 units) 
of the Pod and in units of insulin.
After the patient fills the syringe with insulin, 
s/he injects it into the Pod reservoir through 
the fill port on the bottom of the Pod. The self-
sealing fill septum is designed for single use only. 
Figure 2. Schematic of the OmniPod motor mechanism, 
featuring shape memory alloy (SMA) wire.
Reservoir
SMA wire
Hook
Ratchet
Plunger
Figure 3. A look under the hood, featuring core 
components of the OnmiPod.Diabetes Ther (2010)  1(1):10-24. 15
It is located on the bottom (skin contacting) 
surface of the Pod to eliminate the possibility of 
injecting insulin into the port for a second use. 
Typical pod wear times vary from 48 to 72 hours. 
The pod has the capability of lasting up to 
80 hours to allow for flexibility in changing the 
pod due to unforeseen circumstances.
Cannula Insertion Process
When the patient is ready to attach the Pod, 
s/he removes the adhesive and needle cover from 
the back and sticks the Pod onto the prepared 
site.  By  following  the  PDM’s  screens  and 
pressing specific buttons, the patient tells the 
Pod to activate its insertion mechanism, which 
quickly drives both the insertion needle and 
the soft cannula into the subcutaneous tissue. 
The insertion needle punctures the skin and 
stiffens the cannula during the insertion process. 
When it reaches its forward limit of travel, the 
insertion mechanism retracts and withdraws 
only the needle, leaving the cannula in place at 
the infusion site. The actual insertion takes only 
five 1000ths of a second. The Pod places the soft 
cannula into the patient’s tissue at a 45-degree 
angle, to a depth of 6.5 mm (Figure 4). The 
adhesive pad on the base holds the Pod and the 
cannula in place.
Insulin Delivery
The  PDM  handles  all  processes  for  the 
operation of the system. The display uses full 
text to prompt the user through the set-up and 
use processes. The patient must use the PDM to 
program the Pod with the his/her custom basal 
profile, check the Pod status, initiate a bolus, or 
make changes to the insulin delivery profile. The 
PDM needs to be within 60 cm to communicate 
with the Pod to perform these tasks. After set-up 
and initiation, the Pod runs at the programmed 
basal rate independently of the PDM. If the PDM 
requires the patient’s attention, the Pod sounds 
an alarm beeper.
Incorporated BG Measurement
The PDM incorporates a FreeStyle (Abbott 
Diabetes Care) BG monitor. The BG data is 
stored and its history can be displayed on the 
PDM. For example, a patient’s BG variations 
can be seen in both graphical and list form for 
the past 1, 7, 14, 30, 60, and 90 days. The list 
form shows, for each time period, the average 
number of readings taken, the average BG, the 
minimum and maximum readings, the patient’s 
BG goal range, and the percentage of readings 
within, above, and below that goal. Along with 
insulin delivery records, this information can be 
quite valuable to the physician or nurse when 
reviewing the patient’s status.
Suggested Bolus Calculation
The PDM provides the ability to calculate a 
suggested bolus dosage, which has traditionally 
been done manually by MDI users. Similar 
convenience  features  have  since  been 
incorporated  into  traditional  CSII  pumps. 
The suggested bolus calculation feature is 
provided as a convenience to the user to aid 
in determining the bolus dosage needed based 
on carbohydrates ingested, most recent BG 
reading, user-settable correction factor, insulin-
Figure 4. Catheter view demonstrating 45-degree angle 
and 6.5 mm vertical depth.16 Diabetes Ther (2010)  1(1):10-24.
Table 3. Results of clinical trials and reviews involving the OmniPod Insulin Management System.
Clinical trial report Results
OmniPod Insulin Management System: patient 
perceptions, preference, and glycemic control
Howard Zisser and Lois Jovanovič (2006)1
20 patients currently using CSII switched   •	
to OmniPod System for 30 days.
All patients completed exit questionnaire  •	
comparing using the OmniPod System with  
using their current insulin pump.
90% (18 of 20) preferred using the OmniPod automated cannula  •	
insertion system vs. their current infusion sets.
A1C values decreased from mean of 7.1% to mean of 6.8%  •	
(P<0.002).
Mean responses, on a scale from 1 to 5, where 1 = most favorable  •	
and 5 = least favorable, were:
  Convenience of use = 1.85
  Satisfaction with wearing OmniPod = 1.7
  Satisfaction with current insulin pump = 1.9
  Pain associated with automated cannula insertion = 2.0
  Wearing while sleeping = 1.15
  Wearing while showering = 1.1
  Time involved in Pod change process = 2.05
Quantifying the impact of a short-interval interruption 
of insulin-pump infusion sets on glycemic excursions
Howard Zisser (2008)2
Studied the effect on blood glucose of short  •	
interruptions of basal insulin delivery.
Blood glucose levels rose 1 mg/dL for each minute insulin  •	
infusion was interrupted.
A 30-minute interruption in basal insulin infusion resulted in a  •	
rise of 30 mg/dL 3 hours after reconnecting the insulin pump.
Siphon effects on continuous subcutaneous insulin 
infusion pump delivery performance
Howard Zisser et al. (2010)3
Studied the effect of changing the position of  •	
traditional insulin pumps in relation to the 
position of the cannula on insulin delivery 
accuracy.
Traditional pumps with cannulas showed significant changes  •	
in insulin delivery, ranging from 74.5% of expected delivery 
when pumping towards a site above the pump, to 123.3% when 
pumping downward, at a 1 U/hour rate.
The OmniPod System performed with minimal variation in  •	
insulin delivery, from 99% of expected delivery when pumping 
upward to 101% when pumping downward at the same 1U/hour 
rate.
Clinical experience with a tubing-free insulin pump 
system
Michael Kane et al. (2009)4
Retrospective study of patients who had begun  •	
using the OmniPod System 1 year prior.
Of 59 patients, 47 had used MDI, 12 had used  •	
different brand of pump.
Average A1C values decreased a significant 0.49% ( •	 P<0.01).
25.5% of patients obtained A1C value of <7% after 1 year using  •	
OmniPod System; only 5.7% of patients had obtained that value 
prior to using it.
Reduction of DKA episodes (1 vs. 3). •	
Acceptance rate for the OmniPod was 92.2%. •	
An innovative application of shape memory alloy  
(SMA) technology yields a novel therapeutic approach  
to diabetes management
Steve Dilanni and John Garibotto (2006)5
Technical paper on the enabling technology   •	
for the development of the OmniPod System.
SMA technology applied to the motor of the Pod enables  •	
improved reliability, a more compact system, reduced cost, and 
reduced weight.
SMA wire-actuated motor is unable to “run away” when power  •	
is applied directly, eliminating electromechanical failure and 
increasing accuracy and safety.
(continued on next page)Diabetes Ther (2010)  1(1):10-24. 17
Table 3. (Continued)
Clinical trial report Results
Computer-aided learning in insulin pump training
Sergey Sirotinin and Charles George (2010)6
Study of acceptability of OmniPod interactive  •	
training tool to healthcare professionals 
experienced in diabetes education and certified  
in pump training.
Over a 3-month period, 126 trainers trained  •	
1244 patients on four different brands of insulin 
pump.
All trainers agreed the OmniPod training CD helped patients new  •	
to insulin pump therapy gain a positive attitude toward it.
80% of pump trainers approved of teaching methods used. •	
A prospective trial of U-500 insulin delivered by 
OmniPod in patients with type 2 diabetes and  
severe insulin resistance
Wendy Lane et al. (2010)7
One-year study tested efficacy and safety of  •	
U-500 insulin delivery via the OmniPod System 
to patients with uncontrolled type 2 diabetes and 
severe insulin resistance.
Significant reduction in A1C of 1.23% ( •	 P=0.0008).
Significant increase in percent of time spent within target blood  •	
glucose range, 70 to 180 mg/dL: 70.75% (P=0.0001).
14 of 20 subjects elected to remain on OmniPod at study  •	
completion.
In silico evaluation platform for artificial pancreatic 
beta-cell development—a dynamic simulator for  
closed-loop control with hardware-in-the-loop*
Eyal Dassau et al. (2009)8
Testing of artificial beta-cell systems on computers  •	
usually involves only the controller software; this 
development enables testing of hardware as well.
Allows full-system verification and validation, including hardware  •	
limitations.
Allows systematic analysis of monitoring and control algorithms. •	
Streamlines preclinical validation trials. •	
Closed-loop artificial pancreas using subcutaneous 
glucose sensing and insulin delivery and a model 
predictive control algorithm: preliminary studies in 
Padova and Montpellier*
Daniela Bruttomesso et al. (2009)9
OmniPod System for insulin delivery as part of the Artificial  •	
Pancreas System developed at UCSB/Sansum Diabetes Research.
Closed-loop artificial pancreas using subcutaneous 
glucose sensing and insulin delivery and a model 
predictive control algorithm: the Virginia experience*
William Clarke et al. (2009)10
OmniPod System for insulin delivery as part of the Artificial  •	
Pancreas System developed at UCSB/Sansum Diabetes Research.
*Study funded in part by the Juvenile Diabetes Research Foundation’s Artificial Pancreas Project.
CSII=continuous subcutaneous insulin infusion; DKA=diabetic ketoacidosis; MDI=multiple daily injections.18 Diabetes Ther (2010)  1(1):10-24.
to-carbohydrate ratio, target BG value, and 
duration of insulin action.
DOES THE OMNIPOD 
SYSTEM PROMOTE BETTER 
TYPE 1 DIABETES MANAGEMENT?
CSII delivery, in general, allows for greater 
flexibility in insulin delivery options leading to 
more lifestyle choices related to meal planning 
and exercise. More specifically, I believe the use 
of the OmniPod System contributes to improved 
diabetes management for a variety of reasons, 
including ease of training, setup and insertion, 
uninterrupted and untethered insulin delivery, 
and inclusion of a glucose meter in the PDM. 
An additional advantage of the System may be 
that the Pod, once on the body, does not move 
around much. This results in less fluctuation in 
hydrostatic pressures, ideally leading to more 
consistent insulin delivery. In the near future, 
Insulet Corporation will release in the US a 
modified PDM that receives continuous glucose 
sensing data from the iDex platform (DexCom, 
Inc., San Diego, CA, USA).
In 2005, Dr. Lois Jovanovic ˇ and I performed 
the first clinical evaluation of the OmniPod 
System in 20 subjects with type 1 diabetes.1 (See 
also Table 3 for brief summaries of studies.1-10) 
This 30-day study, supported by a grant from 
Insulet, assessed the comfort, function, and 
use of the System compared with conventional 
insulin pumps. The trial was designed to see how 
the subjects liked the new pump compared to 
their current, traditional CSII pump. We found 
that the subjects much preferred wearing the 
OmniPod System. Ninety percent of subjects (18 
of 20) preferred using the OmniPod automated 
cannula insertion system versus inserting with 
their current infusion sets. What we didn’t 
expect from a month-long pilot study was that 
the vast majority of the subjects had A1C values 
at the end that were significantly lower, dropping 
from a mean of 7.1% (range 5.5-8.1) to a mean 
of 6.8% (range 5.4-7.6; P<0.002). This significant 
change was even more surprising because I had 
not changed the subjects’ pump settings when 
starting them on the OmniPod System.
We expected some “study effect” on the 
subjects’ A1C values but we did not expect that 
large a decrease in such a short time. What could 
be responsible for this improved control despite 
staying on the same pump settings as their 
traditional pump? In a later study, I discovered 
the likely answer to that question.2 One obvious 
difference was that the subjects wearing the 
OmniPod  System  never  disconnected  from 
their pump for any reason other than putting 
on a new Pod when the insulin ran out. CSII 
therapy allows for uninterrupted, around-the-
clock delivery of insulin, but in practice, many 
patients disconnect their insulin pumps from 
their infusion sets when showering, changing 
clothes, swimming, exercising, or during intimate 
moments. Ranging in time from a few minutes 
to several hours, these periods of interrupted 
insulin infusion result in the cessation of basal 
insulin delivery. Interrupting insulin delivery 
may be appropriate during periods of exercise 
when insulin sensitivity increases or during 
hypoglycemia; however, cessation of insulin 
delivery may be detrimental even for short 
periods, especially if it occurs when insulin 
resistance is at its peak. A prospective, open-
label study was designed to measure the impact 
of  short-term  infusion-set  disconnects  and 
infusion-set changes on glucose levels.
Nineteen subjects with type 1 diabetes were 
studied on two separate in-clinic days.2 One 
hour after arriving at the clinic in a fasting state, 
subjects either temporarily disconnected their 
infusion sets from their pumps, interrupting 
basal insulin infusion for 30 minutes, or, on 
a separate day, changed their infusion sets. Diabetes Ther (2010)  1(1):10-24. 19
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Glucose levels were monitored for an additional 
4 hours on both occasions. Changing infusion 
sets did not affect short-term glucose control. 
However, the 30-minute interruption of basal 
insulin infusion resulted in significant glucose 
elevation: 1 mg/dL for each minute basal insulin 
infusion was interrupted.
A second, less obvious difference between 
a  traditional  CSII  pump  and  the  OmniPod 
System is that a traditional pump is tethered 
to the body and therefore moves around in 
relation to the insulin infusion site. Could this 
movement result in changes in insulin delivery? 
A bench-top study was designed to quantify 
these hydrostatic effects on CSII pumps during 
basal and bolus insulin delivery.3 We tested CSII 
pumps from Medtronic Diabetes (MiniMed 512 
and 515), Smiths Medical (Deltec Cozmo 1700), 
and Insulet (OmniPod) using insulin aspart 
(NovoLog, Novo Nordisk).The pumps were filled 
and primed per manufacturer’s instructions. 
The fluid level change was measured using an 
inline graduated glass pipette (100 microliters) 
when the pipette was moved in relation to the 
pump (80 cm Cosmo and 110 cm Medtronics) 
and when level. Pumps were compared during 
1 and 5 U boluses and basal insulin delivery 
of 1.0 and 1.5 U/hour. We found pronounced 
differences that were seen during basal delivery 
in  pumps  using  80-100  cm  tubing.  For  the   
1 U/hour rate, differences ranged from 74.5% 
of  the  expected  delivery  when  the  pumps 
were below the pipettes and pumping upward, 
to 123.3% when the pumps were above the 
pipettes  and  pumping  downward.  For  the   
1.5 U/hour rate, differences ranged from 86.7% to 
117.0% when the pumps were below or above the 
pipettes, respectively. Compared to pumps with 
tubing, the OmniPod System performed with 
significantly less variation in insulin delivery. 
Changing position of a conventional CSII pump 
in relation to its tubing results in significant 
changes in insulin delivery. The siphon effect 
in the tubing may affect the accuracy of insulin 
delivery, especially during low basal rates. This 
effect has been reported when syringe pumps 
were moved in relation to infusion sites but had 
not been reported with CSII pumps. Please note 
that this was a bench-top laboratory evaluation 
without clinical validation. (While the specific 
MiniMed and Deltec pumps used in this study 
are no longer being sold, presumably the same 
siphon effect applies with newer pumps that use 
similar tubing.)
Additional clinical differences may exist than 
those given above. More research may be needed 
to quantify those clinical differences between 
traditionally designed insulin pumps and this 
new category of pump.
REVIEW OF CLINICAL DATA
Clinical Trials and Reviews
Clinical trials like those referred to above 
have demonstrated the effectiveness of Insulet’s 
OmniPod  Insulin  Management  System  in 
managing diabetes. Table 3 lists these and a 
number of other trials and published research 
papers related to the OmniPod System.1-10
Ongoing Research and Development
The OmniPod System is currently in use 
as  part  of  the  Juvenile  Diabetes  Research 
Foundation’s (JDRF) Artificial Pancreas Project 
(APP). This is a global initiative to develop a first-
generation artificial-pancreas therapy model. 
It integrates a continuous BG monitor and an 
insulin pump, with a customized algorithm, to 
deliver the appropriate dose of insulin. Starting 
approximately 3 years ago, the OmniPod System 
continues to be used at the majority of the JDRF-
funded clinical research sites worldwide. The 22 Diabetes Ther (2010)  1(1):10-24.
Table 4. Common patient questions about the OmniPod Insulin Management System.
Question Answer
Is the OmniPod System approved 
for everyone—even children and 
teens?
Yes, the OmniPod is approved for people of all ages who have diabetes and use insulin—including 
children and teens.
Can I swim with the OmniPod 
System?
The watertight Pod can go in the pool, the ocean, the shower, or the tub for up to 7.6 meters (25 feet) 
for 60 minutes with no need to disrupt insulin delivery. The PDM, though, is not waterproof.
Does the OmniPod System 
provide data download capability?
In the US, the OmniPod System downloads insulin delivery, BG, and carbohydrate records to the 
CoPilot® Health Management System, enabling the user to create customized reports, charts, and 
graphs. CoPilot software can be downloaded at no charge. In the EU, other software is available.
Can I travel while using the 
OmniPod System?
Yes. Contact your airline for information on current security requirements. The PDM and Pods can 
safely pass through airport x-ray machines. If the security detector goes off, tell the security screener 
that you have diabetes and wear an insulin Pod.
Can I play sports while wearing 
a Pod?
Yes. You can play sports and participate in physical activities while wearing a Pod—just leave the PDM 
in your gym bag.
How close do the OmniPod 
and the PDM need to be to 
communicate with each other?
For programming insulin delivery or responding to Pod alarms or alerts, the PDM and Pod need to 
be within 61 cm of each other. Otherwise, they do not need to be near each other at all. The Pod will 
continue to deliver your current background (or basal) insulin, even if your PDM is not nearby.
What type of insulin should I use 
with the Pod?
The Pod is designed to be used with U-100 rapid-acting insulin. The following U-100 rapid-acting 
insulin analogs have been tested and found to be safe for use in the Pod: NovoLog®, NovoRapid®, 
Humalog®, or Apidra®. Before using different insulin with the OmniPod System, check the insulin 
drug label to make sure it can be used with a pump and consult with your healthcare professional.
How much insulin does the Pod 
hold?
The Pod holds up to 200 units of insulin; it requires a minimum of 85 units of insulin to begin 
operation.
What type of adhesive does the 
Pod use?
The Pod uses an adhesive similar to the adhesive used with common infusion sets. The adhesive is 
latex-free, acrylic-based, and ideal for holding the Pod, even in the presence of moisture. It is designed 
to hold the Pod securely in place for the duration of wear.
Where on my body can I wear 
the Pod?
The Pod’s automated cannula insertion enables you to wear it many places. It is recommended that you 
begin on your abdomen, because it is easy to access and see what you’re doing. Once you have mastered 
using the Pod, however, you can wear it on your leg, upper thigh, lower back, or the back of your upper 
arm—in fact, anywhere you would give yourself an injection. Of course, you want to avoid wearing the 
Pod within 2 inches of your navel and in other areas where belts, waistbands, or tight clothing may rub 
against, disturb, or dislodge it.
How long do I wear each Pod? A Pod expires 72 hours after activation. You should refer to the insulin labeling and follow your 
healthcare provider’s directions concerning when to replace the Pod.
How long do the batteries last in 
the PDM?
The PDM batteries last approximately 3 weeks. Extensive use of the bright-mode option may shorten 
this time frame.
What if I leave home without my 
PDM or leave it somewhere?
Your Pod will continue to deliver your current background (or basal) insulin, even if you do not have 
your PDM with you. However, you will not be able to make changes to your basal delivery, deliver 
bolus doses, test your BG, or respond to alarms or alerts when your PDM is not with you.
What happens if I lose my PDM? Our experience has been that very few people lose their PDM. However, if you do, please contact 
Insulet Corporation immediately for a replacement. In most cases, you will receive your replacement 
within 24 hours. Of course, some people like to order a back-up PDM to have on hand just in case.
BG=blood glucose; PDM=personal diabetes manager.Diabetes Ther (2010)  1(1):10-24. 23
OmniPod System is also scheduled to be used 
at a number of EU sites as part of the AP@home 
Artificial Pancreas Project.11
COMPARISON WITH OTHER 
INSULIN PUMPS
Figure 5 provides a comparison of the Insulet 
OmniPod System to four traditionally designed 
insulin pumps. Notice especially the list of 
additional features at the end of the table. These 
include the OmniPod System’s tubing-free design, 
innovative  safety  features,  integrated  bolus 
calculator, and many personalized settings.
The OmniPod System may have limitations 
for some users:
Occasional Pod failure does occur. This may  •	
be due to inserting the Pod in a site with 
scar tissue, system failure, occlusion, or 
some other cause.
In extreme heat, the Pod’s adhesive may  •	
not  hold  securely.  As  with  traditional 
infusion sets, the patient may have to add 
extra adhesive.
Some patients are especially self-conscious  •	
and may not want a “bump” on their bodies. 
They may feel they can hide a conventional 
pump more easily, even with tubing and the 
bulk of the pump itself.
Patients who require more than 100 units  •	
of insulin per day may do better choosing a 
pump with a larger, 300-unit reservoir. Some 
may be able to change the Pod every 2 days 
instead of every 3 days.
PATIENT CONCERNS
Patients with diabetes will have concerns 
about using a new device. Table 4 shows the 
answers to some of the most common questions 
patients have. A broader range of questions and 
answers is available online.12
CONCLUSION
For many patients with diabetes, CSII is the 
only way to reach acceptable glucose control 
levels.  The  OmniPod  Insulin  Management 
System improves on the traditional method 
of  delivering  insulin  via  CSII  for  the 
following reasons:
It  frees  patients  with  diabetes  of  being  •	
tethered to their pumps.
It  provides  consistent,  round-the-clock,  •	
uninterrupted insulin delivery.
It allows for easier set up and automated  •	
cannula insertion.
Greater  convenience  often  leads  to  •	
better compliance.
The OmniPod System offers the comfort and 
safety of feedback and alarms, the ability to 
follow daily, monthly, and quarterly progress, 
and the feeling of accomplishment in managing 
one’s  own  diabetes.  Additionally,  patients 
do  not  need  to  be  technologically  “savvy,” 
because the device’s user interface is very clear 
and straightforward. Almost all patients with 
type  1  diabetes  can  benefit  from  using  the 
OmniPod System.
Several next-generation systems are rumored 
to be in development at Insulet Corporation. 
These  systems  include  a  PDM  that  receives 
continuous glucose monitor (CGM) data from 
the DEXCOM 7 Plus continuous glucose sensor, 
a Pod that is over a third smaller in size with the 
same technical features, a Pod that incorporates 
a CGM sensor, and a Pod that has the ability to 
deliver multiple compounds.
The OmniPod platform lends itself to many 
other uses. It is presently being used in Europe 
by Ferring Corporation as a delivery mechanism 
for  an  infertility  drug.  Other  potential 
applications  include:  pain  management; 
chemotherapeutic agents; AIDS, Parkinson’s, 
and multiple sclerosis drugs; biologics; thyroid, 24 Diabetes Ther (2010)  1(1):10-24.
growth hormones, and related peptides; as well 
as in-hospital uses.
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